Jubilant Pharmova Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with stock exchanges on April 1, 2026, demonstrating adherence to regulatory requirements for depositories and participants.

Regulatory Compliance Filing

The certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and submitted to both major Indian stock exchanges. Company Secretary Naresh Kapoor signed and submitted the documentation on behalf of Jubilant Pharmova Limited.

Registrar Confirmation

M/s Alankit Assignments Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate. General Manager Kamal Garg signed the certificate on behalf of Alankit Assignments Limited, providing the required regulatory confirmation.

The registrar's certificate confirms two critical compliance aspects:

• Securities comprised in the certificates have been properly listed on stock exchanges
• Physical certificates have been duly verified, mutilated, cancelled, and depository names substituted as registered owners

Depository Notifications

The filing was also copied to both major depositories in India to ensure comprehensive regulatory compliance. The notifications were sent to National Securities Depository Limited at Trade World, Lower Parel, Mumbai, and Central Depository Services (India) Limited at Marathon Futurex, Lower Parel, Mumbai.

Corporate Information

Jubilant Pharmova Limited operates as part of the Jubilant Bhartia Company group, with its registered office located at Bhartiagram, Gajraula, District Amroha, Uttar Pradesh. The company maintains its corporate identification number as L24116UP1978PLC004624, reflecting its incorporation history and regulatory status.

Jubilant Pharmova Limited has published newspaper advertisements regarding the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF) Authority, following its regulatory filing with stock exchanges. The company submitted copies of these newspaper advertisements to BSE Limited and National Stock Exchange of India Limited on March 31, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Newspaper Publication and Regulatory Compliance

The company published the IEPF transfer notice in Financial Express (English Language – All Editions) and Hindustan & Jansatta (Hindi language) on March 31, 2026. This publication follows the company's earlier regulatory communication submitted on March 30, 2026, ensuring comprehensive shareholder outreach across multiple languages and publications.

IEPF Transfer Requirements and Timeline

Under Section 124(6) of the Companies Act, 2013, read with the IEPF Rules 2016, companies must transfer shares to the IEPF Authority when dividends remain unclaimed for seven consecutive years or more. The company has identified shareholders with unclaimed dividends from financial year 2018-19 onwards, which are scheduled for IEPF transfer.

Critical Dates for Shareholders

Shareholder Action Required

Shareholders with unclaimed dividends must submit applications to Alankit Assignments Limited, the company's Share Transfer Agent, on or before May 15, 2026. The company has uploaded details of affected shareholders on its website at www.jubilantpharmova.com/investors/unclaimed-dividend-and-shares for verification purposes.

Contact Information for Claims

Post-Transfer Recovery Process

Once shares are transferred to IEPF, shareholders retain the right to claim both dividends and shares from the IEPF Authority by filing Form IEPF-5 and following prescribed procedures under the IEPF Rules. All subsequent corporate benefits accruing on transferred shares will also be credited to the IEPF Authority until claimed by rightful shareholders.

Company Secretary Naresh Kapoor has signed the official communications, emphasizing the urgency for shareholders to act before the May 15, 2026 deadline to avoid the transfer process.